About CBR

Since the company’s founding, Cord Blood Registry® (CBR®) has led the industry in technical innovations
and provided families with access to current
treatments and experimental stem cell therapies for
conditions that have no cure.

Weng family
Banked 2012, 2014

Company Overview

Cord Blood Registry (CBR) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing samples from more than 500,000 children. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today.

CBR has helped more than 350 families use their cord blood stem cells for established and experimental medical treatments, more than any other family cord blood bank. CBR’s goal is to expand the potential scope of newborn stem cell therapies that may be available to patients and their families.

Cord Blood Registry is headquartered in San Bruno, California. CBR’s owned 80,000 square foot laboratory is located in Tucson, Arizona.

Cord Blood Registry is a registered trademark of CBR Systems, Inc.

History of Quality

CBR maintains standards for cellular therapy services through AABB accreditation, FDA-registration, and CLIA certification.

CBR has the longest history of accreditation with the AABB (formerly known as the American Association of Blood Banks) and the company’s quality standards have been recognized through ISO 9001:2008 certification — the global business standard for quality.

Advancing Medicine

A pioneer in newborn stem cell collection and cryopreservation, CBR believes in the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future.

CBR is the first family newborn stem cell bank to partner with leading research institutions to establish FDA-regulated clinical trials exploring the potential regenerative ability of stem cells to help treat conditions that have no cure today, including: acquired hearing loss, autism, cerebral palsy, and pediatric stroke. In fact, 73% of the stem cell units released by CBR have been used for experimental regenerative therapies – more than any other family cord blood bank in the world.


CBR created the world’s only collection device designed specifically for cord blood stem cells. CBR’s CellAdvantage® Collection Kit contains everything the healthcare provider needs to help maximize the cord blood collection volume.

CBR developed a crush-resistant, temperature protected, and electronically tracked kit that actively transforms into a cube to encase the blood and/or tissue collection, helping to ensure that it is protected and delivered safely. On average, the transport time from the hospital to CBR’s lab is 19 hours. CBR processes cord blood using the AutoXpress® Platform* (AXP®) — a fully automated, functionally closed stem cell processing technology. CBR has the industry’s highest published average cell recovery rate of 99%.1-3,8

*AXP and AutoXpress are registered trademarks of ThermoGenesis Corp

CBR Executive Team

A team is only as strong as its leadership. Our commitment to helping families starts at the top with our executives.

Todd Van Horn
Todd Van Horn
General Manager of CBR
Senior Vice President of Consumer Marketing & Sales at AMAG Pharmaceuticals, Inc.

Todd Van Horn is an experienced healthcare executive who joined AMAG Pharmaceuticals as part of the company’s recent acquisition of Cord Blood Registry (CBR) and serves as General Manager of CBR and Senior Vice President of Consumer Marketing & Sales at AMAG. Prior to joining AMAG, Mr. Van Horn served as vice president at CBR overseeing its business intelligence team and all business development activities, strategic partnerships, mergers and acquisitions, and collaborations. Prior to joining CBR, he served as a principal at Linden Capital Partners, a healthcare and life sciences-focused private equity firm where he served as a board director or observer on several portfolio companies. Prior to Linden, Mr. Van Horn was a principal and founding member of Healthcare Investment Partners, a growth equity healthcare fund, and began his career in the healthcare investment banking group at Credit Suisse First Boston. Mr. Van Horn holds a bachelor’s of science degree in molecular, cell and developmental biology from the University of California and a master’s of business administration from the Kellogg School of Management.

Heather Brown
Heather Brown
Vice President, Scientific and Medical Affairs

Heather Brown has been with CBR since 2001 and has more than 20 years of clinical and business experience in the healthcare and biotech industries. Heather is a board certified genetic counselor with extensive experience in prenatal, pediatric, and cancer genetics. Heather has led a number of new business development and healthcare marketing initiatives during her tenure at CBR. In her current role, Heather is primarily responsible for research partnerships, clinical trial management, and medical need-based programs. Heather holds a B.A. and M.S. in Health and Medical Sciences from the University of California at Berkeley.

Kristen Swingle
Kristen Swingle
Vice President, Laboratory Operations

Kristen Swingle has been responsible for overseeing all operations at CBR’s laboratory in Tucson, Arizona, since 2007. Mrs. Swingle has a strong background in experimental design, technical writing, and management. In 2006, Mrs. Swingle served as the project lead for the implementation of AXP processing at CBR, working closely with Thermogenesis to optimize this process for our facility. Before coming to CBR, Mrs. Swingle held the position of Microbiology Lab Manager for an environmental testing laboratory. Mrs. Swingle holds a B.S. in Biology and a M.S. in Medical Sciences.

Sign up for free information and special offers. Ready to enroll? Start here, too.